Last reviewed · How we verify
NCT07209241
Different Approaches for CART-EGFR-IL13Ra2 Dosing in Recurrent GBM
Phase 1 trial testing CART-EGFR-IL13Ra2 T cells in Recurrent Glioblastoma in 12 participants. Currently enrolling.
1 November 2042
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 3 December 2025 |
| Primary completion | 1 November 2042 |
| Estimated completion | 1 November 2042 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CART-EGFR-IL13Ra2 T cells — full drug profile →
Conditions studied
- Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
Sponsor
University of Pennsylvania
Who can join
18 and older, any sex, with Recurrent Glioblastoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, phase 1b study to evaluate different approaches for CART-EGFR-IL13Ra2 dosing and further characterize the safety, feasibility, preliminary efficacy, and pharmacokinetics of CART-EGFR-IL13Ra2 cells in patients with EGFR-amplified glioblastoma that has recurred following prior radiotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Smart Cells Against Cancer: Advances in Cell-Based Drug Delivery and Diagnostics.
Gherardini L, Inzalaco G, Gargiulo S, Franci L, et al · · 2025 · PMID 41599135 · DOI 10.3390/pharmaceutics18010028
Verify or expand the search:
- PubMed search for NCT07209241
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Glioblastoma
Currently open trials in the same condition.
- NCT07480941 — Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma · Phase 1 · recruiting
- NCT06910306 — Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma · NA · recruiting
- NCT07193628 — B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma · Phase 1 · recruiting
- NCT07076472 — Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of P · EARLY_PHASE1 · recruiting
- NCT06917885 — CUE-102 in Recurrent Glioblastoma · Phase 1 · recruiting
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07209241 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07209241.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing